AAAAAA

   
Results: 1-25 | 26-38
Results: 1-25/38
Dendritic cells in cancer vaccines
Authors: Brossart, P Wirths, S Brugger, W Kanz, L
Citation: P. Brossart et al., Dendritic cells in cancer vaccines, EXP HEMATOL, 29(11), 2001, pp. 1247-1255
Retraction: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. (vol 333, pg 283, 1995)
Authors: Kanz, L Brugger, W
Citation: L. Kanz et W. Brugger, Retraction: Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. (vol 333, pg 283, 1995), N ENG J MED, 345(1), 2001, pp. 64-64
The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-Lymphocytes
Authors: Brossart, P Schneider, A Dill, P Schammann, T Grunebach, F Wirths, S Kanz, L Buhring, HJ Brugger, W
Citation: P. Brossart et al., The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-Lymphocytes, CANCER RES, 61(18), 2001, pp. 6846-6850
Primary central nervous system lymphoma 1991-1997 - Outcome and late adverse effects after combined modality treatment
Authors: Herrlinger, U Schabet, M Brugger, W Kortmann, RD Kanz, L Bamberg, M Dichgans, J Weller, M
Citation: U. Herrlinger et al., Primary central nervous system lymphoma 1991-1997 - Outcome and late adverse effects after combined modality treatment, CANC CYTOP, 91(1), 2001, pp. 130-135
Primary central nervous system lymphoma 1991-1997 - Outcome and late adverse effects after combined modality treatment
Authors: Herrlinger, U Schabet, M Brugger, W Kortmann, RD Kanz, L Bamberg, M Dichgans, J Weller, M
Citation: U. Herrlinger et al., Primary central nervous system lymphoma 1991-1997 - Outcome and late adverse effects after combined modality treatment, CANCER, 91(1), 2001, pp. 130-135
Signal-regulatory protein alpha (SIRP alpha) but not SIRP beta is involvedin T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells
Authors: Seiffert, M Brossart, P Cant, C Cella, M Colonna, M Brugger, W Kanz, L Ullrich, A Buhring, HJ
Citation: M. Seiffert et al., Signal-regulatory protein alpha (SIRP alpha) but not SIRP beta is involvedin T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells, BLOOD, 97(9), 2001, pp. 2741-2749
Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality
Authors: Hebart, H Brugger, W Grigoleit, U Gscheidle, B Loeffler, J Schafer, H Kanz, L Einsele, H Sinzger, C
Citation: H. Hebart et al., Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality, BLOOD, 97(7), 2001, pp. 2183-2185
Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC)
Authors: Vogel, W Scheding, S Kanz, L Brugger, W
Citation: W. Vogel et al., Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC), STEM CELLS, 18(2), 2000, pp. 87-92
IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group
Authors: Feuring-Buske, M Kneba, M Unterhalt, M Engert, A Gramatzki, M Hiller, E Trumper, L Brugger, W Ostermann, H Atzpodien, J Hallek, M Aulitzky, E Hiddemann, W
Citation: M. Feuring-buske et al., IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group, ANN HEMATOL, 79(9), 2000, pp. 493-500
Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34(+) cells
Authors: Scheding, S Meister, B Buhring, HJ Baum, CM McKearn, JP Bock, T Kanz, T Brugger, W
Citation: S. Scheding et al., Effective ex vivo generation of granulopoietic postprogenitor cells from mobilized peripheral blood CD34(+) cells, EXP HEMATOL, 28(4), 2000, pp. 460-470
Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34(+) cells with stem cell factor and promegapoietin
Authors: Kratz-Albers, K Scheding, S Mohle, R Buhring, HJ Baum, CM Mc Kearn, JP Buchner, T Kanz, L Brugger, W
Citation: K. Kratz-albers et al., Effective ex vivo generation of megakaryocytic cells from mobilized peripheral blood CD34(+) cells with stem cell factor and promegapoietin, EXP HEMATOL, 28(3), 2000, pp. 335-346
Ex vivo manipulation of hematopoietic stem and progenitor cells
Authors: Brugger, W Scheding, S Ziegler, B Buhring, HJ Kanz, L
Citation: W. Brugger et al., Ex vivo manipulation of hematopoietic stem and progenitor cells, SEM HEMATOL, 37(1), 2000, pp. 42-49
PCV salvage chemotherapy for recurrent primary CNS lymphoma
Authors: Herrlinger, U Brugger, W Bamberg, M Kuker, W Dichgans, J Weller, M
Citation: U. Herrlinger et al., PCV salvage chemotherapy for recurrent primary CNS lymphoma, NEUROLOGY, 54(8), 2000, pp. 1707-1708
Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells
Authors: Brossart, P Zobywalski, A Grunebach, F Behnke, L Stuhler, G Reichardt, VL Kanz, L Brugger, W
Citation: P. Brossart et al., Tumor necrosis factor alpha and CD40 ligand antagonize the inhibitory effects of interleukin 10 on T-cell stimulatory capacity of dendritic cells, CANCER RES, 60(16), 2000, pp. 4485-4492
Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia
Authors: Mohle, R Schittenhelm, M Failenschmid, C Bautz, F Kratz-Albers, K Serve, H Brugger, W Kanz, L
Citation: R. Mohle et al., Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia, BR J HAEM, 110(3), 2000, pp. 563-572
Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia
Authors: Denzlinger, C Bowen, D Benz, D Gelly, K Brugger, W Kanz, L
Citation: C. Denzlinger et al., Low-dose melphalan induces favourable responses in elderly patients with high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia, BR J HAEM, 108(1), 2000, pp. 93-95
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells
Authors: Brossart, P Wirths, S Stuhler, G Reichardt, VL Kanz, L Brugger, W
Citation: P. Brossart et al., Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, BLOOD, 96(9), 2000, pp. 3102-3108
May government ever use torture? Two responses from German law
Authors: Brugger, W
Citation: W. Brugger, May government ever use torture? Two responses from German law, AM J COMP L, 48(4), 2000, pp. 661-678
Pre-clinical and early clinical experience using dendritic cells to treat human malignancy
Authors: Kanz, L Brossart, P Stuhler, G Reichardt, V Kleihauer, A Scheding, S Stevanovic, S Einsele, H Rammensee, HG Brugger, W
Citation: L. Kanz et al., Pre-clinical and early clinical experience using dendritic cells to treat human malignancy, HEM CELL TH, 41(2), 1999, pp. 56-57
Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma
Authors: Meister, B Grunebach, F Bautz, F Brugger, W Fink, FM Kanz, L Mohle, R
Citation: B. Meister et al., Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma, EUR J CANC, 35(3), 1999, pp. 445-449
Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma
Authors: Kollmannsberger, C Brugger, W Hartmann, JT Maurer, F Bohm, P Kanz, L Bokemeyer, C
Citation: C. Kollmannsberger et al., Phase II study of oral trofosfamide as palliative therapy in pretreated patients with metastatic soft-tissue sarcoma, ANTI-CANC D, 10(5), 1999, pp. 453-456
Clinical use for expanded peripheral blood steam cells
Authors: Bock, TA Scheding, S Brugger, W Kanz, L
Citation: Ta. Bock et al., Clinical use for expanded peripheral blood steam cells, BAIL CLIN H, 12(1-2), 1999, pp. 117-128
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicinin 100 patients with small-cell lung cancer: A mature follow-up report
Authors: Fetscher, S Brugger, W Engelhardt, R Kanz, L Hasse, J Frommhold, H Lange, W Mertelsmann, R
Citation: S. Fetscher et al., Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicinin 100 patients with small-cell lung cancer: A mature follow-up report, ANN ONCOL, 10(5), 1999, pp. 561-567
Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicinin 107 patients with non-small-cell lung cancer: A mature follow-up report
Authors: Fetscher, S Brugger, W Engelhardt, R Kanz, L Hasse, J Frommhold, H Lange, W Mertelsmann, R
Citation: S. Fetscher et al., Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicinin 107 patients with non-small-cell lung cancer: A mature follow-up report, ANN ONCOL, 10(5), 1999, pp. 605-607
Expression of MUC-1 epitopes on normal bone marrow: Implications for the detection of micrometastatic tumor cells
Authors: Brugger, W Buhring, HJ Grunebach, F Vogel, W Kaul, S Muller, R Brummendorf, TH Ziegler, BL Rappold, I Brossart, P Scheding, S Kanz, L
Citation: W. Brugger et al., Expression of MUC-1 epitopes on normal bone marrow: Implications for the detection of micrometastatic tumor cells, J CL ONCOL, 17(5), 1999, pp. 1535-1544
Risultati: 1-25 | 26-38